First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

PURPOSE: We investigated safety, tolerability, pharmacokinetics, and antitumor activity of the protein tyrosine kinase 7 (PTK7)-targeted, auristatin-based antibody–drug conjugate (ADC) PF-06647020/cofetuzumab pelidotin (NCT02222922). PATIENTS AND METHODS: Patients received PF-06647020 intravenously...

Descripción completa

Detalles Bibliográficos
Autores principales: Maitland, Michael L., Sachdev, Jasgit C., Sharma, Manish R., Moreno, Victor, Boni, Valentina, Kummar, Shivaani, Stringer-Reasor, Erica, Lakhani, Nehal, Moreau, Allison R., Xuan, Dawei, Li, Ray, Powell, Eric L., Jackson-Fisher, Amy, Bowers, Michelle, Alekar, Shilpa, Xin, Xiaohua, Tolcher, Anthony W., Calvo, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401513/
https://www.ncbi.nlm.nih.gov/pubmed/34083232
http://dx.doi.org/10.1158/1078-0432.CCR-20-3757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401513/
https://www.ncbi.nlm.nih.gov/pubmed/34083232
http://dx.doi.org/10.1158/1078-0432.CCR-20-3757

Ejemplares similares